Treatment strategies for ADHD: an evidence-based guide to select optimal treatment

A Caye, JM Swanson, D Coghill, LA Rohde - Molecular psychiatry, 2019 - nature.com
Attention-deficit/hyperactivity disorder (ADHD) is a common and impairing disorder affecting
children, adolescents, and adults. Several treatment strategies are available that can …

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents–assessment of adverse events in non‐randomised studies

OJ Storebø, N Pedersen, E Ramstad… - Cochrane Database …, 2018 - cochranelibrary.com
Background Attention deficit hyperactivity disorder (ADHD) is a common
neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the …

Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit/hyperactivity disorder: a meta-analysis

C Ching, GD Eslick, AS Poulton - JAMA pediatrics, 2019 - jamanetwork.com
Importance Evidence on the titration of stimulant medications for attention-
deficit/hyperactivity disorder (ADHD) is lacking. However, this lack of evidence has not …

[HTML][HTML] Improvement of anxiety in ADHD following goal-focused cognitive remediation: a randomized controlled trial

KT Hanssen, EJ Brevik, MC Småstuen… - Frontiers in …, 2023 - frontiersin.org
Introduction Despite the high prevalence and detrimental consequences of cognitive and
executive dysfunction in ADHD, the evidence base of cognitive remediation in the adult …

A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder

MA Katzman, T Sternat - CNS drugs, 2014 - Springer
Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioural disorder with
onset during childhood. It affects a child's development, both at home and at school, and …

Noradrenergic genes polymorphisms and response to methylphenidate in children with ADHD: a systematic review and meta-analysis

D Yuan, M Zhang, Y Huang, X Wang, J Jiao, Y Huang - Medicine, 2021 - journals.lww.com
Background: Attention-deficit hyperactivity disorder (ADHD) is the most common childhood-
onset neurodevelopmental disorder, and methylphenidate (MPH) is considered one of the …

Personalized medication response prediction for attention-deficit hyperactivity disorder: learning in the model space vs. learning in the data space

HK Wong, PA Tiffin, MJ Chappell, TE Nichols… - Frontiers in …, 2017 - frontiersin.org
Attention-Deficit Hyperactive Disorder (ADHD) is one of the most common mental health
disorders amongst school-aged children with an estimated prevalence of 5% in the global …

[HTML][HTML] Multimodal Interventions Are More Effective in Improving Core Symptoms in Children With ADHD

K Ning, T Wang - Frontiers in psychiatry, 2021 - frontiersin.org
Objective: To investigate the effect of sensory integration training combined with EEG
biofeedback on core symptoms in children with ADHD. Methods: Fifty-two children with …

A randomized, double-blind, placebo-controlled, two-way crossover clinical trial of ORADUR-methylphenidate for treating children and adolescents with attention …

YS Huang, CB Yeh, CH Chen, CY Shang… - Journal of child and …, 2021 - liebertpub.com
Objective: Methylphenidate (MPH) is efficacious in reducing symptoms of attention-
deficit/hyperactivity disorder (ADHD), but there are no data about the efficacy and safety of …

An open-label, self-control, prospective study on cognitive function, academic performance, and tolerability of osmotic-release oral system methylphenidate in children …

Y Zheng, JM Liang, HY Gao, ZW Yang, FJ Jia… - Chinese Medical …, 2015 - mednexus.org
Background: Attention-deficit hyperactivity disorder (ADHD) is the most common mental and
behavioral disorder in school-aged children. This study evaluated the effect of osmotic …